E-Z-CAT

Originaltext auf Französisch.

In Kanada zugelassenes natürliches Gesundheitsprodukt

Zusammensetzung

Nicht arzneiliche Inhaltsstoffe

Carraghénine, Sorbate de potassium, Acide citrique, Sodium Saccharin, citrate de sodium, pectine, Eau purifiée, Simethicone emulsion 30 %, Gomme de xanthane, solution de sorbitol à 70 %, Saveur d'orange, Parahydroxybenzoate de méthyle, Poly(sorbate) 80

In Kanada empfohlene Dosen

In Kanada zugelassene Verwendungen

For computed tomography. Opacification of the GI tract. For use as radiological contrast media for upper and lower gastrointestinal procedures by computed tomography.

Originaltext auf Englisch.

Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.

Warnhinweise in Kanada

Cautions and Warnings : For professional use only. See product information insert for complete details. Do not use if inner seal is broken or missing. Store at controlled room temperature. Diagnostic procedures which involve the use of radiopaque contrast agents should be carried out under the direction of personnel with the requisite training and with a thorough knowledge of the particular procedure to be performed. A history of bronchial asthma, atopy, as evidenced by hay fever and eczema, or a previous reaction to a contrast agent, warrant special attention. Caution should be exercised with the use of radiopaque media in severely debilitated patients and in those with marked hypertension or advanced cardiac disease. Ingestion of barium is not recommended in patients with a history of food aspiration. If barium swallow studies are required in these patients or in patients in whom integrity of the swallowing mechanism is unknown, proceed with caution. Administer initially small amounts such as a half-teaspoon of low-density barium and carefully observe swallowing under fluoroscopic control. If barium is aspirated into the larynx, further administration of barium should be immediately discontinued. If no aspiration is noted, additional barium may be given with continued fluoroscopic monitoring for aspiration. After any barium study of the G.I. tract, it is important to rehydrate the patient as quickly as possible to prevent impaction of the barium. To prevent barium impaction in the colon may also require the use of cathartics following completion of the examination. Saline cathartics are recommended on a routine basis and especially in patients with a history of constipation unless clinically contraindicated. Usage in pregnancy: Radiation is known to cause harm to the unborn fetus exposed in utero. Therefore, radiographic procedures should only be used when, in the judgement of the physician, its use is deemed essential to the welfare of the pregnant patient. Safe use of barium sulfate in pregnancy is not established.

Originaltext auf Englisch.

Contra-Indications : Known or suspected fistula, perforation or obstruction in any part of the gastrointestinal tract, recent rectal biopsy or known hypersensitivity to barium sulphate or any components (see non-medicinal ingredients). Known or suspected fistula, perforation or obstruction in any part of the gastrointestinal tract or recent rectal biopsy. Known hypersensitivity to barium sulfate products is a contraindication to their use. Known hypersensitivity or allergy to latex is a contraindication for the use of latex balloon retention tips. However, all E-Z-EM Canada Inc. products are latex free.

Originaltext auf Englisch.

Known Adverse Reactions : Adverse reactions accompanying the use of barium sulfate formulations are infrequent and usually mild, though severe reactions (approximately 1 in 500,000) and fatalities (approximately 1 in 2,000,000) have occurred. Procedural complications are rare, but may include aspiration pneumonitis, barium impaction, granuloma formation, intravasation, embolization and peritonitis following intestinal perforation, vasovagal and syncopal episodes, and fatalities. EKG changes have been shown to occur following or during barium enemas. It is of the utmost importance to be completely prepared to treat any such occurrence. Allergic reactions: Due to the increased likelihood of allergic reactions in atopic patients, it is important that a complete history of known and suspected allergies as well as allergic-like symptoms, e.g. rhinitis, bronchial asthma, eczema and urticaria, be obtained prior to any medical procedure utilizing the products. A mild allergic reaction would most likely include generalized pruritus, erythema or urticaria (approximately 1 in 100,000 reactions). Such reactions will generally respond to an antihistamine such as 50 mg of diphenhydramine or its equivalent. In the rarer, more serious reactions (approximately 1 in 500,000) laryngeal edema, bronchospasm or hypotension could develop. Severe reactions which may require emergency measures are often characterized by peripheral vasodilation, hypotension, reflex tachycardia, dyspnea, agitation, confusion and cyanosis, progressing to unconsciousness. Treatment should be initiated immediately with 0.3 - 0.5 cc of 1:1000 epinephrine subcutaneously. If bronchospasm predominates, 0.25 - 0.50 gram of intravenous aminophylline should be given slowly. Appropriate vasopressors might be required. Adrenocorticosteroids, even if given intravenously, exert no significant effect on the acute allergic reaction for a few hours. The administration of these steroid agents should not be regarded as emergency measures for the treatment of allergic reactions. Apprehensive patients may develop weakness, pallor, tinnitus, diaphoresis and bradycardia following the administration of any diagnostic agent. Such reactions are usually non-allergic in nature and are best treated by having the patient lie flat for an additional 10 to 30 minutes under observation. All E-Z-EM CANADA INC. products are latex free. Overdosage: In rare occasions following repeated administration, severe stomach cramps and diarrhea may occur. These are transitory in nature and are not considered serious.

Originaltext auf Englisch.

Produktdaten

Andere Namen

Cat Bario, Sufocat

Inhaber

E-Z-EM Canada Inc.

NPN oder DIN-HM

80026294

Status

Aktive Lizenz

Lizenzdatum

11. Juli 2011

Überarbeitungsdatum

26. Juni 2019

Form

Liquide

Verabreichungsweg

Orale

Art des Antrags

Non traditionnelle

Quelle

Amtlicher Health-Canada-Eintrag, Zulassung 80026294

Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Originaltext auf Englisch.

Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.

Liste in der amtlichen Überarbeitung vom 26. Juni 2019 (Register: Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise).

Verpackung fotografieren

Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.